Abstracts tagged "patient outcomes"

Abstract Number: 890 • 2016 ACR/ARHP Annual Meeting
Health-Related Domains of Importance to Patients with Takayasu’s Arteritis
Antoine G. Sreih¹, Fatma Alibaz-Oner², Ebony Easley³, Trocon Davis³, Gonca Mumcu⁴, Nataliya Milman⁵, Joanna C. Robson⁶, Peter F. Cronholm³, Haner Direskeneli⁷ and Peter A. Merkel⁸, ¹Rheumatology, The University of Pennsylvania, Philadelphia, PA, ²Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ³Department of Family Medicine and Community Health, The University of Pennsylvania, Philadelphia, PA, ⁴Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, ⁵Department of Medicine, University of Ottawa, Ottawa, ON, Canada, ⁶Faculty of Health and Applied Science, University of the West of England, Bristol, United Kingdom, ⁷Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁸Division of Rheumatology, Univ of Pennsylvania; Perelman School of Med, Philadelphia, PA
Background/Purpose: The need to include patients’ perspectives as key outcomes in clinical research is now widely recognized. This project was designed to describe the experience…
Abstract Number: 1306 • 2016 ACR/ARHP Annual Meeting
Magnetic Resonance Imaging Measures of Disease Activity in Rheumatoid Arthritis Patients Treated with Multiple Regimens of DMARD Therapy
Paolo Pace¹, Arthur Lau², Jonathan D. Adachi³, Matthew A. Jessome⁴, George Ioannidis² and Minta Patel⁵, ¹Rheumatology, McMaster Unversity, Hamilton, ON, Canada, ²St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada, ⁵Cambridge Memorial Hospital, Cambridge, ON, Canada
Background/Purpose: Magnetic resonance imaging ( MRI ) in rheumatoid arthritis ( RA ) has been shown to be more sensitive than clinical and radiological parameters…
Abstract Number: 1423 • 2016 ACR/ARHP Annual Meeting
Using Self-Reported Patient Experiences to Evaluate Patient Reported Outcomes (PRO) Instruments: Learnings from Digital Patient Communities in Psoriatic Arthritis
Stephen Doogan¹, John Heid², Samir Benosman³, Alexis Ogdie⁴, Layne Martin⁵, Prashanth Sunkureddi⁶ and Jacqueline Palmer⁷, ¹Real Life Sciences, New York, NY, ²Kinapse, Inc, London, United Kingdom, ³Advisory Services, Kinapse, Inc, London, United Kingdom, ⁴University of Pennsylvania, Philadelphia, PA, ⁵CreakyJoints, NY, ⁶Rheumatology, Clear Lake Rheumatology Center, Nassau Bay, TX, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Psoriatic Arthritis (PsA) is a debilitating disease with significant impact on patient quality of life (QoL). While patient reported outcome (PRO) instruments broadly capture…
Abstract Number: 1426 • 2016 ACR/ARHP Annual Meeting
Using Self-Reported Patient Experiences to Understand Patient Burden: Learnings from Digital Patient Communities in Ankylosing Spondylitis
Prashanth Sunkureddi¹, Dawn Gibson², Stephen Doogan³, John Heid⁴, Samir Benosman⁵ and Yujin Park⁶, ¹Rheumatology, Clear Lake Rheumatology Center, Nassau Bay, TX, ²The Global Healthy Living Foundation, Upper Nyack, NY, ³Real Life Sciences, New York, NY, ⁴Kinapse, Inc, London, United Kingdom, ⁵Advisory Services, Kinapse, Inc, London, United Kingdom, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Ankylosing Spondylitis (AS) is a chronic inflammatory disorder of the spinal joints that can lead to severe, chronic pain and discomfort. There is a…
Abstract Number: 1432 • 2016 ACR/ARHP Annual Meeting
The EULAR Systemic Sclerosis Impact of Disease Score – a New Patient-Reported Outcome Measure for Patients with Systemic Sclerosis Under Development
Rucsandra Dobrota¹, Mike Becker², Kim Fligelstone^3,4, Jaap Fransen⁵, Ann Kennedy⁶, Yannick Allanore⁷, Patricia Carreira⁸, László Czirják⁹, Christopher Denton¹⁰, Roger Hesselstrand¹¹, Gunnel Sandqvist¹¹, Otylia Kowal-Bielecka¹², Marco Matucci Cerinic¹³, Carina Mihai¹⁴, Ana Maria Gheorghiu¹⁵, Ulf Müller-Ladner¹⁶, Marc Frerix¹⁷, Turid Heiberg¹⁸ and Oliver Distler¹, ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, ⁴Federation of European Scleroderma Associations (FESCA), London, United Kingdom, ⁵Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ⁶Federation of European Scleroderma Associations (FESCA), Tournai, Belgium, ⁷Department of Rheumatology, University Paris Descartes and Cochin Hospital, Paris, France, ⁸Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁹Department of Rheumatology and Immunology, University of Pécs, Faculty of Medicine, Pécs, Hungary, ¹⁰Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ¹¹Department of Rheumatology, Lund University, Lund, Sweden, ¹²Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, ¹³Department of Rheumatology, University of Florence, Florence, Italy, ¹⁴Department of Internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy, Cantacuzino Hospital, Bucharest, Romania, ¹⁵Carol Davila University of Medicine and Pharmacy, Internal Medicine and Rheumatology Department, Cantacuzino Clinical Hospital, Bucharest, Romania, ¹⁶Department of Internal Medicine and Rheumatology, Justus-Liebig-University Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, ¹⁷Department of Rheumatology and Clinical Immunology, Justus-Liebig-University Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, ¹⁸Department of Health and Social Sciences, Oestfold University College, Oslo, Norway
Background/Purpose: Patient reported outcome measures (PROM) are required as key outcomes in disease modifying therapeutic trials in systemic sclerosis (SSc). A PROM tool in SSc,…
Abstract Number: 1598 • 2016 ACR/ARHP Annual Meeting
Olokizumab Treatment of Both Western and Asian Patients with Rheumatoid Arthritis Who Have Failed Anti-TNF Treatment Results in Sustained Improvements in Patient-Reported Outcomes
Mark C. Genovese¹, Patrick Durez², Roy Fleischmann³, Yoshiya Tanaka⁴, Daniel E. Furst⁵, Hisashi Yamanaka⁶, Igor Vasyutin⁷, Thangavel Kaviarasu⁸, Elena Korneva⁷, Dmitry Koloda⁷ and Tsutomu Takeuchi⁹, ¹Stanford University Medical Center, Palo Alto, CA, ²Department of Rheumatology, Université Catholique de Louvain, Brussels, Belgium, ³Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁵David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁶Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁷R-Pharm CJSC, Moscow, Russian Federation, ⁸Quintiles Inc, Mumbai, India, ⁹School of Medicine, Keio University, Tokyo, Japan
Background/Purpose: Rheumatoid arthritis (RA) has a high patient (pt) burden with significant impact on health-related quality of life. We report the effect of treatment with…
Abstract Number: 1599 • 2016 ACR/ARHP Annual Meeting
Speed of Onset of Effect on Patient-Reported Outcomes Assessed through Daily Electronic Patient Diaries in the Baricitinib Phase 3 RA Clinical Program
Peter C. Taylor¹, Grace C. Wright², Carol L. Gaich³, Amy M. DeLozier³, Stephanie de Bono³, Douglas E. Schlichting³, Terence Rooney³, Jiajun Liu³, Scott D. Beattie⁴ and Maxime Dougados⁵, ¹NDORMS, University of Oxford, Oxford, United Kingdom, ²NYU Langone Medical Center, New York, NM, ³Eli Lilly and Company, Indianapolis, IN, ⁴Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, ⁵Dept of Rheumatology, Cochin Hospital, Paris, France
Background/Purpose: Baricitinib (bari), an oral Janus kinase (JAK) 1/JAK2 selective inhibitor, has demonstrated clinical efficacy with a satisfactory safety profile when administered once daily in…
Abstract Number: 1689 • 2016 ACR/ARHP Annual Meeting
Ixekizumab Provides Improvements through 52 Weeks in Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis
Alice B. Gottlieb¹, M. Elaine Husni², Catherine L. Shuler³, Russel T. Burge³, Chen-Yen Lin³, Chin H. Lee³ and D Gladman⁴, ¹Tufts University School of Medicine, Boston, MA, ²Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ³Eli Lilly and Company, Indianapolis, IN, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: PsA has a negative impact on patients’ quality of life, physical function, and work productivity. Ixekizumab (IXE) is an IgG4 mAb that binds with…
Abstract Number: 430 • 2015 ACR/ARHP Annual Meeting
Adoption of Treat to Target Management in the Context of Achievable Goals and Satisfaction in RA
Peter C. Taylor¹, Juan J Gomez-Reino², Rieke Alten³, Philippe Bertin⁴, Roberto Caporali⁵, Emma Sullivan⁶, Robert Wood⁷, James Piercy⁷, Radu Vasilescu⁸, Dean Spurden⁹ and Jose Alvir¹⁰, ¹Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Botnar Research Centre, Oxford, United Kingdom, ²Desarmen of Rheumatology, Unit Hospital Clinico Universitario, Santiago, Spain, ³Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ⁴Rheumatology, CHU Dupuytren, Limoges, France, ⁵University of Pavia and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ⁶Adelphi Real World, Manchester, United Kingdom, ⁷Adelphi Real World, Macclesfield, United Kingdom, ⁸Medical Affairs, Pfizer Inc, Brussels, Belgium, ⁹Pfizer Inc, Tadworth, United Kingdom, ¹⁰Global Health and Value, Pfizer Inc, New York, NY
Background/Purpose: The approach of setting disease activity targets and adjusting therapy appropriately to achieve the target has been proven to optimize outcomes in Rheumatoid Arthritis…
Abstract Number: 2967 • 2015 ACR/ARHP Annual Meeting
Musculoskeletal Involvement in SSc Correlates with Poor Short Form 36 and SSc Health Assessment Questionnaire Scores As Well As Lower TNF-Alpha Gene Expression in PBMCs
Eliza Pelrine¹, Marie-Dominique Ah-Kioon¹, Meng Zhang², Franck J. Barrat³, Robert F. Spiera³ and Jessica K. Gordon³, ¹Hospital for Special Surgery, New York, NY, ²Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ³Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Systemic Sclerosis (SSc) is characterized by a wide variety of symptoms and disease manifestations including joint pain, gastrointestinal dysfunction, interstitial lung disease, and cardiomyopathy. …
Abstract Number: 651 • 2015 ACR/ARHP Annual Meeting
The Prediction of Long-Term Minimal Disease Activity and Its Benefits in Patients with Psoriatic Arthritis
Philip J. Mease¹, Arthur Kavanaugh², Laura C Coates³, Iain McInnes⁴, Maja Hojnik⁵, Ying Zhang⁶, Jaclyn K. Anderson⁶, Alex Dorr⁶ and Dafna Gladman⁷, ¹Rheumatology Research, Swedish Medical Center, Seattle, WA, ²University of California San Diego, La Jolla, CA, ³Leeds Teaching Hospitals Trust, Leeds, United Kingdom, ⁴University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow, United Kingdom, ⁵AbbVie, Ljubljana, Slovenia, ⁶AbbVie, North Chicago, IL, ⁷Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Minimal disease activity (MDA)1 is a clinically meaningful and comprehensive treatment target for psoriatic arthritis (PsA). The purpose was to determine if baseline (BL)…
Abstract Number: 3151 • 2015 ACR/ARHP Annual Meeting
Validation of Patient-Reported Outcomes Measurement Information System (PROMIS®) Modules for Use in Childhood-Onset Lupus
Jordan T. Jones¹, Janet Wootton², Jun Ying³, Brianna Liberio⁴, Jiha Lee⁵, Adam Carle⁶, Laura Schanberg² and Hermine I. Brunner⁶, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Pediatrics, Duke Medical Center, Durham, NC, ³University of Cincinnati, Cincinnati, OH, ⁴University of Cincinnati College of Medicine, Cincinnati, OH, ⁵Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Childhood-onset lupus (cSLE) has a substantial negative impact on health-related quality of life (HRQoL). Patient-reported outcomes (PROs) that accurately assess HRQoL and are responsive…
Abstract Number: 658 • 2015 ACR/ARHP Annual Meeting
Health Related Quality of Life in Psoriatic Arthritis from the Perspective of People Living with the Condition
Ana-Maria Orbai^1,2, Suzanne Grieb³, Clifton Bingham⁴, Michelle Jones⁴, Grazyna Purwin⁵ and Katherine Clegg-Smith⁶, ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Johns Hopkins Bayview Medical Center, Center for Child and Community Health Research, Baltimore, MD, ⁴Johns Hopkins University, Baltimore, MD, ⁵Johns Hopkins Arthritis Center, Baltimore, MD, ⁶Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
Background/Purpose: Psoriatic arthritis (PsA) is a complex inflammatory disease with variable phenotype affecting skin, joints, ligaments/tendons, nails, and the spine. Heterogeneity of clinical manifestations complicates…
Abstract Number: 677 • 2015 ACR/ARHP Annual Meeting
Satisfaction in Psoriatic Arthritis Patients Despite Active Joint Disease
Daniel E. Furst¹, Emma Sullivan², James Pike³, James Piercy⁴, Jacqueline Palmer⁵ and Vivian Herrera⁵, ¹Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Adelphi Real World, Manchester, United Kingdom, ³Statistics, Adelphi Real World, Macclesfield, United Kingdom, ⁴Adelphi Real World, Macclesfield, United Kingdom, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Psoriatic Arthritis (PsA) is a chronic immune-mediated condition with multiple manifestations; joint inflammation with subsequent joint damage is a key component. Across a number…
Abstract Number: 679 • 2015 ACR/ARHP Annual Meeting
Patients with Psoriatic Arthritis and Oligoarthritic Subtype Report Higher Disease Burden Than Patients with a Polyarthritic Pattern – Data from the German Collaborative Arthritis Centres
Dörte Huscher¹, Katinka Albrecht², Sascha Bischoff², Katja Thiele², Frank Behrens³, Kathrin Fischer⁴, Ulrich von Hinüber⁵, Susanna Späthling-Mestekemper⁶, Siegfried Wassenberg⁷ and Angela Zink¹, ¹German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ²German Rheumatism Research Centre, Berlin, Germany, ³CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, ⁴Praxis fuer Innere Medizin, Aerztehaus Schoenwalde, Greifswald, Germany, ⁵Practice-based rheumatologist, Hildesheim, Germany, ⁶Practice-based rheumatologist, München, Germany, ⁷Rheumaklinik, Themistocles Gluck hospital - Rheumazentrum Ratingen, Ratingen, Germany
Background/Purpose: Psoriatic arthritis (PsA) divides into different subtypes, of which polyarthritis and spondylitis would be expected with the highest disease severity. We compared disease burden…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].